NCT03026569

Brief Summary

This study aimed to verify whether orange juice, source of citrus flavonoids and vitamin C, may contribute to the treatment of patients with chronic hepatitis C.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
43

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2012

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2012

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2012

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2012

Completed
4.4 years until next milestone

First Submitted

Initial submission to the registry

January 17, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

January 20, 2017

Completed
Last Updated

January 23, 2017

Status Verified

January 1, 2017

Enrollment Period

2 months

First QC Date

January 17, 2017

Last Update Submit

January 20, 2017

Conditions

Keywords

orange juicechronic hepatitis Cbiochemical markersoxidative stressnutritional statusantioxidants

Outcome Measures

Primary Outcomes (1)

  • Total cholesterol

    8 weeks

Secondary Outcomes (17)

  • Body mass

    8 weeks

  • Body mass index

    8 weeks

  • % body fat

    8 weeks

  • Waist circumference

    8 weeks

  • Glucose

    8 weeks

  • +12 more secondary outcomes

Study Arms (2)

Orange juice

EXPERIMENTAL

Orange juice: twenty-three patients with chronic hepatitis C under pegylated interferon combined with ribavirin treatment were supplemented with 100% commercial pasteurized orange juice (500 mL/d) during 8 weeks.

Other: Orange juice (500 mL/d)

Control

NO INTERVENTION

Control: twenty patients with chronic hepatitis C under pegylated interferon combined with ribavirin treatment were monitored for consumption of orange juice during 12 weeks.

Interventions

The patients were instructed to drink orange juice in two daily portions during eight consecutive weeks. Patients from both groups were asked to maintain their usual lifestyle, diet, and physical activity, and they were checked weekly by the researcher's team. Assessments of anthropometric data, dietary intake, as well as blood sample collection for biochemical analysis were performed in all participants on the first and last day of the experiment.

Orange juice

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Detection of circulating HCV RNA
  • Negative HBV surface antigen
  • Negative antibodies to HIV

You may not qualify if:

  • Co-infection with hepatitis B virus (HBV)
  • Co-infection with hepatitis A virus (HAV)
  • Co-infection with human immunodeficiency virus (HIV)
  • Presence of diabetes mellitus,
  • Presence of ascites
  • Elevation in serum ferritin levels

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sao Paulo State University "Julio de Mesquita Filho"

Araraquara, São Paulo, 14800-903, Brazil

Location

Related Publications (1)

  • Dourado GK, Cesar TB. Investigation of cytokines, oxidative stress, metabolic, and inflammatory biomarkers after orange juice consumption by normal and overweight subjects. Food Nutr Res. 2015 Oct 20;59:28147. doi: 10.3402/fnr.v59.28147. eCollection 2015.

    PMID: 26490535BACKGROUND

MeSH Terms

Conditions

Persistent InfectionHepatitis C, Chronic

Condition Hierarchy (Ancestors)

InfectionsDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsHepatitis CBlood-Borne InfectionsCommunicable DiseasesHepatitis, Viral, HumanVirus DiseasesFlaviviridae InfectionsRNA Virus InfectionsHepatitis, ChronicHepatitisLiver DiseasesDigestive System DiseasesChronic Disease

Study Officials

  • Thais B Cesar, Ph.D

    Sao Paulo State University "Julio de Mesquita Filho"

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD

Study Record Dates

First Submitted

January 17, 2017

First Posted

January 20, 2017

Study Start

May 1, 2012

Primary Completion

July 1, 2012

Study Completion

September 1, 2012

Last Updated

January 23, 2017

Record last verified: 2017-01

Locations